Description

PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist studied in laboratory research focused on neuroendocrine signaling and receptor-mediated pathway activation. It is derived from melanocortin peptide analog development and serves as a research tool for melanocortin system analysis.

Biochemical Characteristics

PT-141 is a cyclic peptide designed to interact with melanocortin receptors, particularly MC3R and MC4R. Its structure supports receptor affinity and intracellular signaling activation in controlled experimental models. The peptide is commonly evaluated for receptor binding kinetics and second messenger pathway activation.

Research Applications

PT-141 is utilized in studies examining melanocortin receptor pharmacology, neuropeptide signaling behavior, and GPCR-mediated intracellular cascades. It is applied in experimental models focused on central receptor signaling and neuroendocrine pathway regulation.

Pathway / Mechanistic Context

Mechanistic research explores PT-141–mediated activation of melanocortin receptors and subsequent cAMP-dependent signaling pathways. Studies evaluate receptor sensitivity, intracellular signaling responses, and regulatory feedback mechanisms within melanocortin systems.

Preclinical Research Summary

Preclinical investigations have examined PT-141 in in vitro and experimental models to assess melanocortin receptor activation and neuroendocrine signaling modulation.

Form & Analytical Testing

PT-141 is supplied as a lyophilized peptide and undergoes analytical verification, including HPLC testing, to confirm identity, purity, and consistency for laboratory research use.

RUO Disclaimer

This product is intended strictly for research and laboratory use only. It is not approved for human consumption, medical treatment, veterinary use, cosmetic application, or diagnostic purposes. Handling should be performed only by qualified professionals trained in proper laboratory procedures.